DEA区块MMJ生物药厂的大麻种植进行临床试验,但因程序有缺陷而遭到批评。 DEA blocks MMJ BioPharma's cannabis cultivation for clinical trials, facing criticism for flawed process.

美国缉毒署(DEA)因阻止MMJ生物药剂种植公司注册在临床试验中种植符合联邦标准的大麻而面临批评。 The U.S. Drug Enforcement Administration (DEA) faces criticism for blocking MMJ BioPharma Cultivation's registration to grow federally compliant cannabis for clinical trials. 尽管该公司批准并遵守了食品和药品管理局的决定,但药品管理局的决定缺乏适当的听证,与最高法院的裁决相矛盾。 Despite the company's FDA approvals and compliance, the DEA's decision lacked a proper hearing and contradicted Supreme Court rulings. 此案凸显了缉毒局内部法院系统的问题,司法部现在放弃了对这一结构的辩护。 The case highlights issues with the DEA's internal court system, with the Department of Justice now abandoning its defense of this structure. 最后决定权属于缉毒署署长Terrance Cole。 The final decision rests with DEA Administrator Terrance Cole.